Hemodynamic Changes in Connective Tissue Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01468792

Enrollment

Registered

2011-11-09

Start date

2011-09-30

Completion date

2014-02-28

Last updated

2014-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Sclerosis

Keywords

systemic sclerosis, pulmonary arterial hypertension

Brief summary

The study serves the identification of early forms of pulmonary arterial hypertension (PAH) in connective tissue disease and the hemodynamic follow-up of the investigated patients. The basic hypothesis is that PAH may start with a remodeling of small pulmonary arteries, which leads to a stiffening of the vessels, indicated by the inability to vasodilatation and thus a disproportional increase in pulmonary pressure during exercise. Recent studies have shown that a proportion of such patients may develop manifest PAH within a few years. The early identification of these patients and the understanding of the natural course of the disease may improve prognosis. The aim of the present study is to investigate hemodynamic and clinical changes in patients with connective tissue disease in a time interval of 3-5 years with a focus on the development of pulmonary hypertension.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Informed consent * Patients with systemic sclerosis, mixed connective tissue disease, (systemic lupus erythematodes) SLE or overlap syndrome * Existing exercise Doppler echocardiography or/and right heart catheterization 3-5 years before inclusion

Exclusion criteria

* \- Severe lung or bronchial disease (FEV1 \<60%) * Systolic LV dysfunction (LVEF \<50%) or diastolic dysfunction \> grade I * Valvular defect \> grade I (except for tricuspid- or pulmonary insufficiency) * Uncontrolled systemic arterial hypertension (at rest \>150 mmHg systolic or 95 mmHg diastolic) * Uncontrolled ventricular arrhythmias * Uncontrolled bradycardia or tachycardia supraventricular arrhythmias * Myocardial infarction within the last 12 months * Pulmonary embolism within the last 12 months * Relevant changes in hemodynamic therapy or major surgery within the last 12 weeks * Musculoskeletal or peripheral vessel disorders which complicates an ergometry

Design outcomes

Primary

Measure	Time frame	Description
systolic pulmonary pressure at 50 W	3-5 years	change of systolic pulmonary arterial pressure after 3-5 years

Secondary

Measure	Time frame	Description
peak (oxygen uptake) VO2	3-5 years	change of peak VO2 after 3-5 years

Countries

Austria

Outcome results